MA47126A - Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4 - Google Patents
Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4Info
- Publication number
- MA47126A MA47126A MA047126A MA47126A MA47126A MA 47126 A MA47126 A MA 47126A MA 047126 A MA047126 A MA 047126A MA 47126 A MA47126 A MA 47126A MA 47126 A MA47126 A MA 47126A
- Authority
- MA
- Morocco
- Prior art keywords
- acetylcholin
- muscarinic
- receptor
- positive allosteric
- allosteric modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662418663P | 2016-11-07 | 2016-11-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA47126A true MA47126A (fr) | 2019-10-30 |
Family
ID=62076580
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA047126A MA47126A (fr) | 2016-11-07 | 2017-11-07 | Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4 |
Country Status (7)
Country | Link |
---|---|
US (1) | US10961253B2 (fr) |
EP (1) | EP3558309B1 (fr) |
JP (1) | JP7099725B2 (fr) |
CN (1) | CN109862893B (fr) |
BR (1) | BR112018013763A2 (fr) |
MA (1) | MA47126A (fr) |
WO (1) | WO2018085808A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112018003417B1 (pt) | 2016-06-22 | 2023-10-24 | Vanderbilt University | Composto modulador alostérico positivo do receptor muscarínico de acetilcolina m4 e composição farmacêutica que o compreende |
MA46899A (fr) | 2016-11-07 | 2021-04-14 | Univ Vanderbilt | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 |
MA46722A (fr) | 2016-11-07 | 2019-09-11 | Univ Vanderbilt | Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4 |
TW201930311A (zh) | 2017-12-05 | 2019-08-01 | 泛德比爾特大學 | 蕈毒鹼型乙醯膽鹼受體m4之正向別構調節劑 |
IL299758A (en) * | 2020-07-15 | 2023-03-01 | Univ Vanderbilt | History of 7-(piperidin-1-yl)-4H-pyrimidio[2,1-B]pyridazin-4-one as positive allosteric modulators of the M4 muscarinic acetylcholine receptor |
WO2023114224A1 (fr) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combinaison de modulateurs positifs du récepteur muscarinique et de modulateurs allostériques positifs de nmda |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5594001A (en) | 1993-04-08 | 1997-01-14 | The Dupont Merck Pharmaceutical Company | Polycyclic systems, and derivatives thereof, as neurotransmitter release enhancers useful in the treatment of cognitive disorders |
US5679683A (en) | 1994-01-25 | 1997-10-21 | Warner-Lambert Company | Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
IL112248A0 (en) * | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
AU2001231154A1 (en) | 2000-01-24 | 2001-07-31 | Adherex Technologies Inc. | Peptidomimetic modulators of cell adhesion |
US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
US20020123485A1 (en) | 2000-07-27 | 2002-09-05 | Alexander John C. | Epoxy steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure |
US7291733B2 (en) | 2003-10-10 | 2007-11-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted tricyclic heterocycles and their uses |
US20090099165A1 (en) | 2003-10-14 | 2009-04-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein Kinase Inhibitors |
SI1678166T1 (sl) | 2003-10-14 | 2009-10-31 | Univ Arizona State | Inhibitorji proteinske kinaze |
PE20060526A1 (es) | 2004-06-15 | 2006-07-13 | Schering Corp | Compuestos triciclicos como antagonistas de mglur1 |
EP1619196A1 (fr) | 2004-07-23 | 2006-01-25 | Curacyte Discovery GmbH | Pyrido[3',2':4,5]thieno[3,2-d]pyrimidines et Pyrido[3',2':4,5]furo[3,2-d]-pyrimidines substitués comme inhibiteurs de PDA-4 et/ou libération de TNF-alpha |
ATE455777T1 (de) | 2004-07-23 | 2010-02-15 | Medicines Co Leipzig Gmbh | Substituierte pyridoä3',2':4,5üthienoä3,2- düpyrimidine und pyridoä3',2':4,5üfuroä3,2-dü- pyrimidine zur verwendung als inhibitoren der pda-4 und/oder tnf-alpha freisetzung |
DK1807434T3 (da) | 2004-10-25 | 2010-11-22 | Lilly Co Eli | Thienopyridiner som allosteriske potentiatorer af M4- muscarinreceptoren |
ES2259892B1 (es) | 2004-11-30 | 2007-11-01 | Laboratorios Almirall S.A. | Nuevos derivados de piridotienopirimidina. |
ES2259891B1 (es) | 2004-11-30 | 2007-11-01 | Laboratorios Almirall S.A. | Nuevos derivados de piridotienopirimidina. |
WO2006138418A2 (fr) | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Amelioration de la performance cognitive avec des activateurs de sirtuine |
AR059901A1 (es) | 2006-03-20 | 2008-05-07 | Bayer Pharmaceuticals Corp | Compuestos de tetrahidropiridotienopirimidina utiles para tratar o prevenir trastornos proliferativos celulares. |
CA2654842A1 (fr) | 2006-06-12 | 2007-12-21 | Vertex Pharmaceuticals Incorporated | Thienopyrimidines utiles en tant que modulateurs de canaux ioniques |
US8153803B2 (en) * | 2006-07-18 | 2012-04-10 | The General Hospital Corporation | Compositions and methods for modulating sirtuin activity |
US20080021063A1 (en) | 2006-07-18 | 2008-01-24 | Kazantsev Aleksey G | Compositions and methods for modulating sirtuin activity |
US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
CA2946305C (fr) | 2006-12-29 | 2019-09-17 | Rigel Pharmaceuticals, Inc. | Triazoles substitues utilises comme inhibiteurs d'axl |
US20090105240A1 (en) | 2007-10-17 | 2009-04-23 | Tomas Mustelin | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same |
US20100009934A1 (en) | 2008-06-09 | 2010-01-14 | Combinatorx, Incorporated | Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders |
JP5746172B2 (ja) | 2009-08-20 | 2015-07-08 | カルス セラピューティクス リミテッド | ホスホイノシチド3−キナーゼ阻害剤としての三環式複素環化合物 |
US20110178107A1 (en) | 2010-01-20 | 2011-07-21 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
WO2012131297A1 (fr) | 2011-03-28 | 2012-10-04 | Jonathan Bayldon Baell | Dérivés de pyrido[3',2':4,5]thiéno[3,2-d]pyrimidin-4-ylamine et leur utilisation thérapeutique |
WO2013040534A1 (fr) * | 2011-09-16 | 2013-03-21 | Vanderbilt University | Analogues de 1h-pyrazolo[3',4',4,5]thiéno[2,3-b]pyridin-3-amine substitués à titre de modulateurs allostériques positifs du récepteur muscarinique m4 de l'acétylcholine |
US20130116241A1 (en) | 2011-11-09 | 2013-05-09 | Abbvie Inc. | Novel inhibitor compounds of phosphodiesterase type 10a |
WO2013096820A1 (fr) | 2011-12-21 | 2013-06-27 | The Regents Of The University Of Colorado | Composés anticancéreux ciblant des gtpases ral et leurs procédés d'utilisation |
US8697888B2 (en) | 2012-01-06 | 2014-04-15 | Vanderbilt University | Substituted (1-(methylsulfonyl)azetidin-3-yl)(heterocycloalkyl)methanone analogs as antagonists of muscarinic acetylcholine M1 receptors |
US9493481B2 (en) | 2012-02-23 | 2016-11-15 | Vanderbilt University | Substituted 5-aminothieno[2,3—C]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4 |
WO2014011902A1 (fr) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Inhibiteurs d'irak et leurs utilisations |
US9056875B2 (en) | 2012-08-31 | 2015-06-16 | Vanderbilt University | Substituted pyrazolo[3′,4′:4,5]thieno[2,3-C]pyridazin-3-amine analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4 |
WO2015027204A1 (fr) | 2013-08-23 | 2015-02-26 | Vanderbilt University | Analogues de thiéno[2,3-b]pyridine-2-carboxamide substitués à utiliser en tant que modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 |
WO2015027214A1 (fr) | 2013-08-23 | 2015-02-26 | Vanderbilt University | Analogues de thiéno[2,3-c]pyridazine-6-carboxamide substitués utilisés en tant que modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 |
US9981920B2 (en) | 2014-06-26 | 2018-05-29 | Rodin Therapeutics, Inc. | Inhibitors of histone deacetylase |
BR112018003417B1 (pt) | 2016-06-22 | 2023-10-24 | Vanderbilt University | Composto modulador alostérico positivo do receptor muscarínico de acetilcolina m4 e composição farmacêutica que o compreende |
MA46722A (fr) | 2016-11-07 | 2019-09-11 | Univ Vanderbilt | Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4 |
MA46899A (fr) | 2016-11-07 | 2021-04-14 | Univ Vanderbilt | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 |
-
2017
- 2017-11-07 JP JP2019522981A patent/JP7099725B2/ja active Active
- 2017-11-07 US US16/347,450 patent/US10961253B2/en active Active
- 2017-11-07 EP EP17867920.5A patent/EP3558309B1/fr active Active
- 2017-11-07 BR BR112018013763-4A patent/BR112018013763A2/pt not_active Application Discontinuation
- 2017-11-07 WO PCT/US2017/060324 patent/WO2018085808A1/fr unknown
- 2017-11-07 MA MA047126A patent/MA47126A/fr unknown
- 2017-11-07 CN CN201780066090.6A patent/CN109862893B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
BR112018013763A2 (pt) | 2018-12-11 |
JP7099725B2 (ja) | 2022-07-12 |
EP3558309A4 (fr) | 2020-07-01 |
EP3558309A1 (fr) | 2019-10-30 |
CN109862893A (zh) | 2019-06-07 |
US20190330225A1 (en) | 2019-10-31 |
WO2018085808A1 (fr) | 2018-05-11 |
CN109862893B (zh) | 2023-02-17 |
JP2019537590A (ja) | 2019-12-26 |
EP3558309B1 (fr) | 2023-07-26 |
US10961253B2 (en) | 2021-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA45463A (fr) | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 | |
MA44253A (fr) | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m1 | |
MA46722A (fr) | Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4 | |
MA47126A (fr) | Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4 | |
DK3452448T3 (da) | Modulatorer af den integrerede stressvej | |
MA43756A (fr) | Modulateurs allostériques des récepteurs nicotiniques de l'acétylcholine | |
PT3452454T (pt) | Moduladores da via integrada ao stresse | |
MA47127A (fr) | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 | |
MA46899A (fr) | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 | |
IL264951B (en) | Positive allosteric modulators of the m1 muscarinic receptor | |
BR112017026561A2 (pt) | moduladores alostéricos positivos do receptor muscarínico m2 | |
MA44236A (fr) | Anticorps anti-tgfbêta 2 | |
MA52555A (fr) | Modulateurs du récepteur des oestrogènes | |
DK3411001T3 (da) | Dentalinstrumentbro med ny visningsanordning | |
MA51036A (fr) | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 | |
MA50464A (fr) | Amides polycycliques utilisés en tant que modulateurs allostériques positifs du récepteur muscarinique m1 | |
HUE036698T2 (hu) | Mérõeszközök regisztrálása az interneten keresztül | |
MA51037A (fr) | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 | |
IT201700039369A1 (it) | Dispositivo per il calcolo dell'indice bispettrale | |
UA36196S (uk) | Тяга верхня навісного пристрою транспортного засобу | |
ES1184294Y (es) | Tapón vertedor antigoteo | |
ITUA20163954A1 (it) | "integrazione dell'ordine logico" | |
UA34712S (uk) | Дюбель-хомут «вертоліт» для кріплення кабелю | |
FR3045913B1 (fr) | Element pour la construction d'un module d'harmonica | |
UA34620S (uk) | Іграшка - конструктор «мост» |